XOMA (NASDAQ:XOMA) Cut to Sell at StockNews.com

XOMA (NASDAQ:XOMA) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Separately, HC Wainwright restated a “buy” rating and set a $123.00 price objective on shares of XOMA in a research report on Friday, December 13th.

XOMA Price Performance

NASDAQ:XOMA traded down $0.98 on Friday, hitting $26.30. The company had a trading volume of 11,277 shares, compared to its average volume of 22,988. XOMA has a 52 week low of $18.24 and a 52 week high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $309.89 million, a price-to-earnings ratio of -7.56 and a beta of 0.88. The firm has a 50 day moving average of $29.82 and a two-hundred day moving average of $27.80.

Insiders Place Their Bets

In other news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Several institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares during the period. Geode Capital Management LLC raised its position in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 1,138 shares in the last quarter. State Street Corp lifted its stake in shares of XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the period. Finally, Ellsworth Advisors LLC bought a new stake in shares of XOMA during the 3rd quarter valued at about $516,000. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.